Skip to main content

Table 3 Clinical characteristics of thyroid dysfunction related to PD-1 monoclonal antibody therapy in primary liver cancer

From: Immune checkpoint blockade PD-1 therapy for primary liver cancer: incidence and influencing factors of thyroid dysfunction

 

Hyperthyroidism

(n = 20)

Hypothyroidism

(n = 93)

P

t/ x2/Z

Gender (n, %)

  

0.460

1.057

 Male

17(85.0)

69(74.2)

  

 Female

3(15.0)

24(25.8)

  

Age(years,x ± s)

56.5 ± 8.1

58.9 ± 11.1

0.353

0.933

BMI

23.7 ± 2.9

23.3 ± 3.6

0.729

0.348

Diabetes

  

1.000

0.000

 Yes

3(15.0)

15(16.1)

  

 No

17(85.0)

78(83.9)

  

Evaluation time [weeks,M(Q1,Q3)]

14.0(9.0, 29.5)

11.0(3.0, 25.5)

0.117

1.566

Hepatocellular carcinoma (n,%)

  

0.347

-

 Yes

20(100.0)

85(91.4)

  

 No

0(0.0)

8(8.6)

  

Staging of BCLC system(n,%)

  

1.000

0.000

 B

4(15.0)

21(19.4)

  

 C

16(85.5)

72(80.6)

  

HBV or HCV(n,%)

19(77.4)

83(85.0)

0.710

0.138

Cirrhosis (n,%)

18(80.5)

65(87.8)

0.384

0.759

Decompensation stage (n,%)

6(33.3)

61(65.6)

0.010

6.559

 Yes

12(66.7)

32(34.4)

  

 No

    

Previous or combined treatment (n,%)

7(35.0)

9(9.7)

0.003

8.684

 Surgical resection

16(80.0)

69(74.2)

0.585

0.298

 TAE or TACE

11(55.0)

44(47.3)

0.533

1.389

 Tumor ablation

13(85.0)

64(68.8)

0.740

0.110

 Targeted agent

0(0.0)

6(6.5)

0.588

-

 Systemic chemotherapy

1(5.0)

13(14.0)

0.464

0.535

 Radiotherapy

0(0.0)

13(14.0)

0.120

-

Name of PD-1 monoclonal antibody (n,%)

  

0.827

0.048

 Sintilimab

10(50.0)

49(52.7)

  

 Camrelizumab

10(50.0)

44(47.3)

  

Thyroid antibody (n,%)

  

1.000

0.000

 Positive

2(22.2)

5(20.0)

  

 Negative

7(77.9)

20(80.0)

  
  1. BCLC:Barcelona Clinic Liver Cancer; TAE: transarterial embolization;TACE: transar-terial chemoembolization; PD-1: programmed cell death protein 1; TSH: abnormal thyroid stimulating hormone; FT4: free thyroxine 4; FT3: free thyroxine 3